Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ONC-392
DRUG
2 trials
Sponsors
OncoC4, Inc.
Conditions
Adenoid Cystic Carcinoma
Advanced Solid Tumor
Cervical Cancer
Esophageal Cancer
Fallopian Tube Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
High Grade Serous Adenocarcinoma of Ovary
+14 more
Phase 1
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Active, not recruiting
NCT04140526
OncoC4, Inc.
Adenoid Cystic Carcinoma, Advanced Solid Tumor, Cervical Cancer +16
Start: 2020-09-16
End: 2027-12-31
Target: 733
Updated: 2026-09-14
Phase 2
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Active, not recruiting
NCT05446298
OncoC4, Inc.
Fallopian Tube Cancer, High Grade Serous Adenocarcinoma of Ovary, Ovarian Cancer +1
Start: 2022-12-22
End: 2026-08-30
Updated: 2026-04-13
Related Papers
Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab.
Journal of Clinical Oncology
2026-05-27
Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors.
Journal of Clinical Oncology
2025-05-28
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors
Regular and Young Investigator Award Abstracts
2023-10-31
1 citations
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.
Journal of Clinical Oncology
2023-06-01
6 citations
594 Dose escalation of next generation anti-CTLA-4 antibody ONC-392 in combination with fixed dose of pembrolizumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts
2022-11-01
564 Safety and clinical activities of the acid pH-sensitive anti-CTLA-4 mAb ONC-392 in ovarian cancer patients
Regular and Young Investigator Award Abstracts
2022-11-01
949 First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients
2021-11-01
4 citations
231 Molecular insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392
Regular and Young Investigator Award Abstracts
2021-11-01
2 citations
533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors
Regular and Young Investigator Award Abstracts
2021-11-01
First-in-human phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy.
Journal of Clinical Oncology
2020-05-20
1 citations